Urol. praxi. 2020;21(4):182-186 | DOI: 10.36290/uro.2020.029

Immunotherapy in the bladder cancer treatment: long-term results

MUDr. Petr Hušek, FEBU1, MUDr. Jaroslav Pacovský, Ph.D.1, MUDr. Miroslav Podhola, Ph.D.2, prof. MUDr. Miloš Broďák, Ph.D.1
1 Urologická klinika UK a FN Hradec Králové
2 Fingerlandův ústav patologie UK a FN Hradec Králové

Aim: BCG is an attenuated mycobacterium developed as a vaccine for tuberculosis that has demonstrated antitumor activity in BC (bladder cancer) intravesical instillation after comlete endoresection of tumor (TURT), and significantly reduces the progression risk of high grade NMIBC and CIS. Aim of article was an evaluation of 82 patients who underwent BCG procedure in our clinical center between 2001-2017.

Methods: We retrospectively evaluated age, gender, tumor size, smoking, CIS presence, recurrence and progression EORT score in time resection. Patients were divided to two groups: BCG success and BCG failure. BCG failure group are patients with recurrence high grade tumor and CIS or with progression to MIBC or died due to bladder cancer during follow-up.

Results: Time of follow-up was from 2 to 13 years. BCG success was demonstrated by 68 % patients, and BCG failure by 32 % patients. There was recurrence in 23 % patients and progression in 9 %. 5 % patients died due to bladder cancer. An average time to failure of BCG therapy was 10 months.

Conclusion: We confirmed good clinical outcomes BCG instillation therapy for patients with high grade NMIBC and CIS with low rate side effects.

Keywords: BCG, bladder cancer, CIS.

Received: June 8, 2020; Revised: June 8, 2020; Accepted: June 8, 2020; Prepublished online: June 8, 2020; Published: January 6, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hušek P, Pacovský J, Podhola M, Broďák M. Immunotherapy in the bladder cancer treatment: long-term results. Urol. praxi. 2020;21(4):182-186. doi: 10.36290/uro.2020.029.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002; 168(5): 1964-1970. Go to original source... Go to PubMed...
    2. htp://www.svod.cz.
    3. Compérat E, Larré S , Roupret M, Neuzillet Y,Pignot G, Quintens H, Houéde N, Roy C, Durand X, Varinot J, Vordos D, Rouanne M, Bakhri MA, Bertrand P, Jeglinschi SC, Cussenot O, Soulié M, Pfister C. Clinicopathological characteristic of urothelial bladder cancer in patient sless than 40 year sold. Virchows Arch 2015; 466(5): 589-94. doi: 10.1007/s00428-015-1739-2. Epub2015Feb 20. Go to original source...
    4. Oosterlinck W, Kurth KH, Schröder F, Bultinck J, Hammond B, Sylvester R. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol 1993; 149(4): 749-753. Go to original source... Go to PubMed...
    5. Sylvester RJ, Oosterlinck W, Holmang S, Sydes MR, Birtle A, Gudjonsson S, De Nunzio C, Okamura K, Kaasinen E, Solsona E, Ali-El-Dein B, Tatar CA, Inman BA, N'Dow J, Oddens JR, Babjuk M. Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation? Eur Urol 2016; 69(2): 231-44. doi: 10.1016/j.eururo.2015.05.050. Epub 2015 Jun 16. Go to original source... Go to PubMed...
    6. Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 1976; 116(2): 180-183. Go to original source... Go to PubMed...
    7. Lamm DL, Thor DE, Harris SC, Reyna JA, Stogdill VD, Radwin HM. Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. J Urol 1980; 124(1): 38-40. Go to original source... Go to PubMed...
    8. Drake T, Hicks J. BCG in bladder cancer: the morales of the story. Eur Urol Suppl 2014; 13; e334. Go to original source...
    9. Herr HW, Morales A. History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story. J Urol 2008; 179(1): 53-56. Epub 2007 Nov. Go to original source... Go to PubMed...
    10. Oddens J, Brausi M, Sylvester R, Bono A, van de Beek C, van Andel G, Gontero P, Hoeltl W, Turkeri L, Marreaud S, Collette S, Oosterlinck W. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate - and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol 2013; 63(3): 462-472. doi: 10.1016/j.eururo.2012.10.039. Epub 2012 Nov 2. Go to original source... Go to PubMed...
    11. Martínez-Piñeiro L, Portillo JA, Fernández JM, Zabala JA, Cadierno I, Moyano JL, Solsona E, Unda M, Beardo P, Rodríguez-Molina J, Chantada V, Palou J, Muntañola P, Alonso Dorrego JM, Pérez-Garcia FJ, Silva JM, Chesa N, Montesinos M, Ojea A, Madero R, Martínez-Piñeiro JA. Maintenance Therapy with 3-monthly Bacillus Calmette-Guérin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non-muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013. Eur Urol 2015; 68(2): 256-62. doi: 10.1016/j.eururo.2015.02.040. Epub 2015 Mar 18. Go to original source... Go to PubMed...
    12. van der Meijden AP, Sylvester RJ, Oosterlinck W, Hoeltl W, Bono AV; EORTC Genito-Urinary Tract Cancer Group. Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol 2003; 44(4): 429-434. Go to original source... Go to PubMed...
    13. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006; 49(3): 466-465; discussion 475-7. Epub 2006 Jan 17. Go to original source... Go to PubMed...
    14. Cabello MJ, Grau L, Franco N, Orenes E, Alvarez M, Blanca A, Heredero O, Palacios A, Urrutia M, Fernández JM, López-Beltrán A, Sánchez-Carbayo M. Multiplexed methylation profiles of tumor suppressor genes in bladder cancer. J Mol Diagn 2011; 13(1): 29-40. doi: 10.1016/j.jmoldx.2010.11.008. Epub 2010 Dec 23. Go to original source... Go to PubMed...
    15. García-Baquero R, Puerta P, Beltran M, Alvarez-Mújica M, Alvarez-Ossorio JL, Sánchez-Carbayo M. Methylation of tumor suppressor genes in a novel panel predicts clinical outcome in paraffin-embedded bladder tumors. Tumour Biol 2014; 35(6): 5777-5786. doi: 10.1007/s13277-014-1767-6. Epub 2014 Feb 28. Go to original source... Go to PubMed...
    16. Ibragimova I, Dulaimi E, Slifker MJ, Chen DY, Uzzo RG, Cairns P. A global profile of genes promoter methylation in treatment-naïve urothelial cancer. Epigenetics 2014; 9(5): 760-773. Go to original source... Go to PubMed...
    17. Friedrich MG, Chandrasoma S, Siegmund KD, Weisenberger DJ, Cheng JC, Toma MI, Huland H, Jones PA, Liang G. Prognostic relevance of methylation markers in patients with non-muscle invasive bladder carcinoma. Eur J Cancer 2005; 41(17): 2769-78. Epub 2005 Oct 19. Go to original source... Go to PubMed...
    18. Chmelarova M, Krepinska E, Spacek J, Laco J, Beranek M, Palicka V. Methylation in the p53 promoter in epithelial ovarian cancer. Clin Transl Oncol 2013; 15(2): 160-163. doi: 10.1007/s12094-012-0894-z. Epub 2012 Jul 19. Go to original source... Go to PubMed...
    19. Chmelařová M, Křepinská E, Spaček J, Laco J, Nekvindová J, Palička V. Methylation analysis of tumour suppressor genes in ovarian cancer using MS-MLPA. Folia Biol (Praha) 2012; 58(6): 246-50. Go to original source... Go to PubMed...
    20. Agundez M, Grau L, Palou J, Algaba F, Villavicencio H, Sanchez-Carbayo M. Evaluation of the methylation status of tumour suppressor genes for predicting bacillus Calmette-Guérin response in patients with T1G3 high-risk bladder tumours. Eur Urol 2011; 60(1): 131-40. doi: 10.1016/j.eururo.2011.04.020. Epub 2011 Apr 16. Go to original source... Go to PubMed...
    21. Alvarez-Múgica M, Fernández-Gómez JM, Cebrian V, Fresno F, Escaf S, Sánchez-Carbayo M. Polyamine-modulated factor-1 methylation predicts Bacillus Calmette-Guérin response in patients with high-grade non-muscle-invasive bladder carcinoma. Eur Urol 2013; 63(2): 364-70. doi: 10.1016/j.eururo.2012.05.050. Epub 2012 Jun 5. Go to original source... Go to PubMed...
    22. Husek P, Pacovsky J, Chmelarova M, Podhola M, Brodak M. Methylation status as a predictor of intravesical Bacillus Calmette-Guérin (BCG) immunotherapy response of high grade non-muscle invasive bladder tumor. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2017; 161(2): 210-216. doi: 10.5507/bp.2017.008. Epub 2017 Mar 22. Go to original source... Go to PubMed...
    23. Kulkarni GS, Hakenberg OW, Gschwend JE, Thalmann G, Kassouf W, Kamat A, Zlotta A. An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. Eur Urol 2010; 57(1): 60-70. doi: 10.1016/j.eururo.2009.08.024. Epub 2009 Sep 1. Go to original source... Go to PubMed...
    24. Takenaka A, Yamada Y, Miyake H, Hara I, Fujisawa M. Clinical outcomes of bacillus Calmette-Guérin instillation therapy for carcinoma in situ of urinary bladder. Int J Urol 2008; 15(4): 309-313. doi: 10.1111/j.1442-2042.2008.02012.x. Go to original source... Go to PubMed...
    25. Kaasinen E, Wijkström H, Malmström PU, Hellsten S, Duchek M, Mestad O, Rintala E. Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a nordic study. Eur Urol. 2003; 43(6): 637-645. Go to original source... Go to PubMed...
    26. Solsona E, Iborra I, Ricós JV, Monrós JL, Dumont R, Almenar S. Extravesical involvement in patients with bladder carcinoma in situ: biological and therapy implications. J Urol 1996; 155(3): 895-899; discussion 899-900. Go to original source... Go to PubMed...
    27. Daniels MJ, Barry E, Schoenberg M, Lamm DL, Bivalacqua TJ, Sankin A, Kates M. Contemporary oncologic outcomes of second induction course BCG in patients with nonmuscle invasive bladder cancer. Urol Oncol 2019: S1078-1439(19)30218-2. doi: 10.1016/j.urolonc.2019.05.018. [Epub ahead of print] Go to original source... Go to PubMed...
    28. Herr HW, Dalbagni G. Defining bacillus Calmette-Guerin refractory superficial bladder tumors. J Urol 2003; 169(5): 1706-1708. Go to original source... Go to PubMed...
    29. Zahoor H, Mir MC, Barata PC, Stephenson AJ, Campbell SC, Fergany A, Dreicer R, Garcia JA. Phase II trial of continuous treatment with sunitinib in patients with high-risk (BCG-refractory) non-muscle invasive bladder cancer. Invest New Drugs 2019; 37(6): 1231-1238. doi: 10.1007/s10637-018-00716-w. Epub 2019 Jun 24. Go to original source... Go to PubMed...
    30. Han RF, Pan JG. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 2006; 67(6): 1216-1223. Go to original source... Go to PubMed...
    31. Shelley MD, Wilt TJ, Court J, Coles B, Kynaston H, Mason MD. Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int 2004; 93(4): 485-490. Go to original source... Go to PubMed...
    32. Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002; 168(5): 1964-1970. Go to original source... Go to PubMed...
    33. Lamm DL Carcinoma in situ. Urol Clin North Am 1992; 19(3): 499-508. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.